The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.

Bousser, M G;Amarenco, P;Chamorro, A;Fisher, M;Peeters, André;et.al.
(2009) Cerebrovascular Diseases — Vol. 27, n° 6, p. 608-613 (2009)

Files

2009-Performbaselinecharacteristicspopulation.pdf
  • Restricted Access
  • Adobe PDF
  • 118.42 KB
Request a copy

Details

Authors
  • Bousser, M G
    Author
  • Amarenco, P
    Author
  • Chamorro, A
    Author
  • Fisher, M
    Author
  • Peeters, AndréUCLouvain
    Collaborator
Show more
Abstract
The PERFORM study population is homogeneous in terms of demographic and disease characteristics. With 19,119 patients, the PERFORM study is powered to test the superiority of terutroban over aspirin in the secondary prevention of cerebrovascular and cardiovascular events in patients with a recent history of ischemic stroke or transient ischemic attack.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bousser, M. G., Amarenco, P., Chamorro, A., Fisher, M., Ford, I., Fox, K., Hennerici, M., Mattle, H. P., & Rothwell, P. M. (2009). The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovascular Diseases, 27(6), 608-613. https://doi.org/10.1159/000216835 (Original work published 2009)